317 articles
Gemigliptin
Gemigliptin (Zemiglo, 제미글로; LC15-0444) is a once-daily 50 mg DPP-4 inhibitor for type 2 diabetes, developed by LG Life Sciences and first approved in Korea in June 2012 as Korea's first domestically developed anti-diabetic new drug.
Gender-affirming hormone therapy
Gender-affirming hormone therapy (GAHT) is the medical administration of estrogen or testosterone, with adjunct antiandrogens or GnRH agonists, to align secondary sex characteristics with a person's gender identity.
Gestodene
Gestodene (GSD), a third-generation synthetic progestin developed by Schering, used with ethinylestradiol in combined oral contraceptives such as Femodene and Millinette; most potent progestin per weight, 75 mcg dose, VTE risk about 50-80% higher than levonorgestrel pills, not US-approved.
GKM-001
GKM-001 is a liver-selective glucokinase activator for type 2 diabetes, discovered by Advinus Therapeutics (India) and later held by Impetis Biosciences; it lowers glucose without raising insulin or causing hypoglycemia.
Glibenclamide
Glibenclamide (glyburide), a second-generation sulfonylurea introduced in 1969, lowers glucose by closing beta-cell KATP channels; used in type 2 diabetes, MODY, and high-dose neonatal diabetes, with notable hypoglycemia risk and placental transfer.
Glibornuride
Glibornuride (Glutril, Ro 6-4563) is a second-generation sulfonylurea antidiabetic drug, ATC A10BB04, formula C18H26N2O4S, MW 366.5, introduced 1969; it blocks SUR1 K(ATP) channels on pancreatic beta cells to stimulate insulin secretion.
Glutazumab (格鲁塔珠单抗)
Glutazumab (格鲁塔珠单抗, GMA102/GMA105) is Gmax Biopharm's long-acting GLP-1/anti-GLP-1R antibody fusion protein agonist, in phase III in China for type 2 diabetes and in earlier trials for obesity.
Gosogliptin
Gosogliptin (PF-00734200) is a potent, selective difluoropyrrolidine DPP-4 inhibitor developed by Pfizer for type 2 diabetes, licensed to SatRx and registered in Russia in 2016.
Govorestat
Govorestat (AT-007), also known as Nugalviq in Europe, is an investigational CNS-penetrant aldose reductase inhibitor by Applied Therapeutics for galactosemia, SORD deficiency, and PMM2-CDG; FDA CRL November 2024, EU application withdrawn, studies halted April 2026.
Gugulipid (guggulsterone-standardized guggul extract)
Gugulipid, a guggulsterone E/Z-standardized extract of Commiphora mukul oleoresin developed by CDRI Lucknow and approved in India as a lipid-lowering drug; FXR-antagonist mechanism, but a 2003 US trial found LDL-C rose.
HEC88473
HEC88473 (APL-18881) is Sunshine Lake Pharma's investigational long-acting GLP-1/FGF21 dual-receptor agonist Fc fusion protein injection for type 2 diabetes, obesity, and MASH; first such dual agonist in clinical stage, licensed to Apollo Therapeutics.
Henagliflozin proline
Henagliflozin proline (脯氨酸恒格列净, brand name Ruiqin) is an oral SGLT2 inhibitor by Jiangsu Hengrui Pharmaceuticals, approved in China in 2021 and described as the first SGLT2 inhibitor developed independently there.
Histrelin
Histrelin acetate (Supprelin LA, Vantas) is a GnRH agonist nonapeptide delivered as a once-yearly subcutaneous hydrogel implant, used for central precocious puberty and advanced prostate cancer.
HRS-1596
HRS-1596 (Hengrui Pharma) is a phase 1-ready oral GLP-1R/GIPR dual agonist for once-weekly dosing in obesity and type 2 diabetes, licensed to Novo Nordisk on 29 September 2026 for up to $2.6 billion excluding Greater China.
HRS-4729
HRS-4729 (KAI-4729) is Hengrui's once-weekly injectable GLP-1/GIP/glucagon tri-agonist peptide for obesity, licensed to Kailera outside Greater China; its Phase 1 trial showed 16.0% weight loss at 12 weeks.
HRS-5346
HRS-5346 (MK-7262) is Hengrui's oral small-molecule lipoprotein(a) inhibitor, licensed to MSD outside Greater China for $200 million upfront; Phase 2 in China cut Lp(a) up to 86% at 12 weeks.
HRS-7249
HRS-7249: GalNAc-conjugated APOC3-targeting siRNA injection by Hengrui's Shanghai Tuojie unit, in phase 2 China trials for hyperlipidemia and severe hypertriglyceridemia; phase 1 TG cuts of 62-75%.
HRS-7535
HRS-7535 is Jiangsu Hengrui's once-daily oral small-molecule (nonpeptide) GLP-1 receptor agonist for type 2 diabetes and weight management; phase 2 trials showed HbA1c cuts up to 1.57% and weight loss up to 9.36%, with a China NDA accepted in 2026.
HRS9531 (瑞普泊肽)
HRS9531 (瑞普泊肽, ribupatide, KAI-9531) is Jiangsu Hengrui's once-weekly dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes; phase 3 showed 19.2% weight loss at 48 weeks, with NDAs filed in China.
HS-10535
HS-10535, also known as MK-4082, is an investigational oral small-molecule GLP-1 receptor agonist for obesity developed by China's Hansoh Pharma and globally licensed to Merck & Co. in December 2024.
HS-20094
HS-20094 (olatorepatide, 奥莱泊肽) is Hansoh Pharma's once-weekly dual biased GLP-1/GIP receptor agonist for diabetes and obesity, licensed to Regeneron outside Greater China; Phase 3 showed up to 19.3% weight loss at 48 weeks.
Hybutimibe
Hybutimibe (海博麦布, hyzetimibe, HS-25; brand Saisimei) is an oral NPC1L1 cholesterol absorption inhibitor made by Zhejiang Hisun, approved in China June 2021 for primary hypercholesterolemia, dosed 10 or 20 mg daily, adding about 16% LDL-C reduction to statins.
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate (17-OHPC; Delalutin, Makena, Proluton Depot) is a synthetic long-acting progestin ester given weekly by intramuscular injection. FDA approved it in 2011 to prevent recurrent preterm birth and withdrew that approval in April 2023; the EU suspended it in 2024.
Imiglitazar
Imiglitazar (TAK-559) is a Takeda dual PPARα/γ agonist (glitazar) for type 2 diabetes; phase 3 development was discontinued in 2004 after liver enzyme abnormalities, and it was never approved.
IMPACTonIMT trial
IMPACTonIMT (NCT01291641) trial: randomized Korean-Chinese study of probucol, or probucol plus cilostazol, added to statins in coronary artery disease; no carotid IMT benefit at 3 years.
Inclisiran
Inclisiran (brand name Leqvio) is a small interfering RNA drug targeting PCSK9 that lowers LDL cholesterol, given by subcutaneous injection twice a year and used with statins in adults with high cholesterol.
Insulin (medication)
Insulin (medication): injectable pancreatic hormone used to control blood glucose in diabetes, essential in type 1 diabetes. Types span rapid-acting (15-minute onset) to ultra long-acting (36+ hours); biosimilars Merilog and Kirsty approved 2025; discovered Toronto 1921, Nobel 1923.
Insulin and noiiglutide fixed-dose combination (舒地胰岛素诺利糖肽)
舒地胰岛素诺利糖肽 (HR17031) is Hengrui's once-daily fixed-ratio injection of basal insulin sudelidec (INS068) plus the GLP-1 receptor agonist noiiglutide for type 2 diabetes; NMPA accepted its NDA in March 2026 after two positive phase 3 trials versus insulin glargine.
Insulin aspart
Insulin aspart (NovoRapid, NovoLog, Fiasp) is a rapid-acting insulin analog for mealtime diabetes therapy, made by replacing proline B28 with aspartic acid; second FDA-approved rapid-acting analog, with biosimilars Merilog and Garzulys.
Insulin degludec
Insulin degludec (Tresiba, IDeg) is Novo Nordisk's ultra-long-acting basal insulin analog, EU-approved 2013 and FDA-approved 2015, with >42 h action, multihexamer depot release, glargine-equivalent HbA1c control, and lower nocturnal hypoglycemia.